Mark William Lowdell - 18 Nov 2025 Form 4 Insider Report for Inmune Bio, Inc. (INMB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
18 Nov 2025, 17:29:25 UTC
Prior SEC filing
09 Dec 2024
Next SEC filing
02 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Mark William Lowdell

Key filing fact

Mark William Lowdell filed Form 4 for Inmune Bio, Inc. (INMB) on 18 Nov 2025.

Key facts

  • This page summarizes Mark William Lowdell's Form 4 filing for Inmune Bio, Inc. (INMB).
  • 10 reported transactions and 10 derivative rows are listed below.
  • Accepted by SEC: 18 Nov 2025, 17:29.

Change

  • Previous filing in this sequence was filed on 09 Dec 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001767037 Primary reporting owner

Lowdell Mark William

Relationship
Chief Scientific Officer
Address
C/O INMUNE BIO INC., 225 NE MIZNER BLVD., SUITE 640, BOCA RATON
Signature
/s/ Mark William Lowdell
Signature date
18 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INMB transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-400,000
Change %
-100%
Price
Shares after
0
Date
18 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
400,000
Exercise price
$7.80
Footnotes
F1, F2
INMB transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+400,000
Change %
Price
Shares after
400,000
Date
18 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
400,000
Exercise price
$1.50
Footnotes
F1, F2
INMB transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-180,000
Change %
-100%
Price
Shares after
0
Date
18 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
180,000
Exercise price
$3.91
Footnotes
F1, F2
INMB transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+180,000
Change %
Price
Shares after
180,000
Date
18 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
180,000
Exercise price
$1.50
Footnotes
F1, F2
INMB transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-104,000
Change %
-100%
Price
Shares after
0
Date
18 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
104,000
Exercise price
$7.92
Footnotes
F1, F2
INMB transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+104,000
Change %
Price
Shares after
104,000
Date
18 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
104,000
Exercise price
$1.50
Footnotes
F1, F2
INMB transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-140,000
Change %
-100%
Price
Shares after
0
Date
18 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
140,000
Exercise price
$5.05
Footnotes
F1, F2
INMB transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+140,000
Change %
Price
Shares after
140,000
Date
18 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
140,000
Exercise price
$1.50
Footnotes
F1, F2
INMB transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-100,000
Change %
-100%
Price
Shares after
0
Date
18 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
100,000
Exercise price
$9.92
Footnotes
F1, F2
INMB transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+100,000
Change %
Price
Shares after
100,000
Date
18 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
100,000
Exercise price
$1.50
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

Footnote F2

This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .